## MO: Altria Group, Inc. - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_10 -3.2% below STRENGTH zone (3.0-6.0%); PEG 4.01 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($56.01)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Altria Stock (MO) News: Dividend Reset, FDA on! PLUS Authorization, and NJOY Legal Battleâ€”What Investors Need Before Monday**
- Source: ts2.tech | 20251228T202847 | Somewhat-Bullish | Relevance: 100%
- Altria (MO) is navigating several key factors as investors prepare for Monday's trading, including a recent ex-dividend date that has impacted its short-term stock price. The company also secured a significant regulatory win with FDA authorization for its on! PLUS nicotine pouches, while its NJOY e-vapor business continues to face legal challenges, specifically a patent dispute with Juul Labs. Investors are also watching broader market trends, such as year-end momentum and upcoming Federal Reserve minutes, which could influence defensive, dividend-heavy stocks like Altria.

**2. Altria Stock: Navigating Dividends, Buybacks, and Technical Concerns**
- Source: AD HOC NEWS | 20251228T080531 | Neutral | Relevance: 100%
- Altria Group Inc. presents a mixed picture for investors as 2025 concludes, balancing robust shareholder returns with cautions from technical indicators. The company offers a significant dividend yield of approximately 7.4% and an aggressive $2 billion share repurchase program. However, the stock is showing "overbought" signals with an RSI above 80, suggesting potential for a near-term pullback, while a CEO transition further adds to the long-term considerations.

**3. Altria Group Stock (MO) Slides After Ex-Dividend Session as Investors Track NJOY Legal Fight and FDA Green Light for on! PLUS Nicotine Pouches**
- Source: ts2.tech | 20251227T151000 | Somewhat-Bearish | Relevance: 100%
- Altria Group (MO) shares fell 2.34% on Friday, closing at $57.60, a movement partly attributed to the stock trading ex-dividend on December 26th. The company also faces ongoing litigation regarding its NJOY vaping business, with Juul Labs seeking to block Altria's use of certain records. Simultaneously, the FDA recently authorized six on! PLUS nicotine pouch products, a significant development for Altria's smoke-free portfolio, though public health scrutiny on nicotine remains.

**4. Altria (MO) Stock After Hours on Dec. 24, 2025: Dividend Deadline, Unusual Options Surge, and FDA Nicotine Pouch Catalyst Before the Next Market Open**
- Source: ts2.tech | 20251225T010834 | Somewhat-Bullish | Relevance: 100%
- Altria (MO) stock showed a modest gain on Christmas Eve, with significant after-hours trading activity as investors focused on its upcoming ex-dividend date of December 26, 2025, for a $1.06 quarterly payout. The trading session also saw an unusual surge in call options volume, and the recent FDA authorization for Altria's "on! PLUS" nicotine pouch products continues to be a key catalyst for its smoke-free narrative. With markets closed on Christmas Day, the next open on December 26 will be critical for dividend mechanics and potential price adjustments.

**5. Altria Group (MO) Stock: What to Know Before the U.S. Market Opens on Dec. 26, 2025**
- Source: ts2.tech | 20251226T025515 | Neutral | Relevance: 100%
- This article outlines key information for Altria Group (MO) investors before the December 26, 2025 market open, focusing on its ex-dividend date, recent FDA authorization for on! PLUS nicotine pouches, and the upcoming CEO transition. Despite declining cigarette volumes, the company's "smoke-free" strategy and robust dividend remain central to its investment case.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 34.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 9.5% (-0.4%)
- Blackrock Inc.: 7.5% (+2.4%)
- State Street Corpora: 4.3% (-0.9%)
- Charles Schwab Inves: 3.5% (-4.7%)
- Geode Capital Manage: 2.7% (+1.2%)

### Key Risks

1. Valuation stretched: PEG 4.0x requires aggressive growth execution.
2. Long-term trend broken: trading 5.1% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Share repurchase program provides demand floor and EPS support.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.01 signals overvaluation risk, limited margin of safety. Forward P/E 10.3x stretched relative to 3% growth. Quality metrics strong (ROA 22%, margin 44%). Balance sheet: $3.0B free cash flow. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $96.8B |
| Beta | 0.50 |
| 52W Range | $50.08 - $68.60 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.01 |
| Forward P/E | 10.3 |
| Current P/E | 10.6 |
| YoY Growth | 2.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.1% to -3.2% (-2.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.2pp (needs >3.0% for momentum thesis). Below SMA200 (0.95x), long-term trend not supportive. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.21% (CS: 8) | Weak |
| RSI_14 | 39.6 | Neutral |
| MACD Histogram | 0.04 | Bullish |
| vs SMA20 | 0.983x | Below |
| vs SMA50 | 0.971x | Below |
| vs SMA200 | 0.949x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $57.63
- **Stop Loss:** $56.01 (2.8% risk)
- **Target:** $59.25 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 339
- **Position Value:** $19,536.57
- **Portfolio %:** 19.54%
- **Risk Dollars:** $550.00
- **Risk Per Trade:** 0.55%
- **Modifiers:** L1 110% | L2 50% | Combined 0.55x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-01-29 (Est: $1.32)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.45 | $1.45 | +0.1% |
| 2025Q2 | $1.38 | $1.44 | +4.0% |
| 2025Q1 | $1.19 | $1.23 | +3.5% |
| 2024Q4 | $1.28 | $1.29 | +0.9% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*